About Acidic leucine-rich nuclear phosphoprotein 32 family member A
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) is a protein
from Homo sapiens identified by UniProt accession
P39687, 249 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Acidic leucine-rich nuclear phosphoprotein 32 family member A |
|---|
| UniProt accession | P39687 |
|---|
| Gene | ANP32A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 249 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- Agents acting on the renin-angiotensin system use measurement · score 0.23
- esophageal carcinoma · score 0.20
- acute myeloid leukemia · score 0.08
- oral squamous cell carcinoma · score 0.07
- Spinal cord injury · score 0.06
- neoplasm · score 0.05
- hepatocellular carcinoma · score 0.05
- scrapie · score 0.04
- non-small cell lung carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P39687-F1 | alphafold | PREDICTED | 79.91 | — |
Amino-acid sequence (249 residues)
MEMGRRIHLE LRNRTPSDVK ELVLDNSRSN EGKLEGLTDE FEELEFLSTI NVGLTSIANL PKLNKLKKLE LSDNRVSGGL EVLAEKCPNL THLNLSGNKI KDLSTIEPLK KLENLKSLDL FNCEVTNLND YRENVFKLLP QLTYLDGYDR DDKEAPDSDA EGYVEGLDDE EEDEDEEEYD EDAQVVEDEE DEDEEEEGEE EDVSGEEEED EEGYNDGEVD DEEDEEELGE EERGQKRKRE PEDEGEDDD
Explore Acidic leucine-rich nuclear phosphoprotein 32 family member A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets